Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration

International Ophthalmology

Volumn 29, Issue 5, 2009, Pages 349-357

  Levy, Jaime ^a   Shneck, Marina ^a   Rosen, Shirley ^b   Klemperer, Itamar ^a   Rand, David ^c   Weinstein, Orly ^a   Pitchkhadze, Anry ^a   Belfair, Nadav ^a   Lifshitz, Tova ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Avastin; Choroidal neovascularization; Intravitreal bevacizumab; Prognostic factors

Indexed keywords

BEVACIZUMAB;

AGE; AGED; ARTICLE; CASE STUDY; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE INJURY; FEMALE; HUMAN; INTERVENTION STUDY; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PROGNOSIS; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SHORT COURSE THERAPY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; RETINA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 70349852926     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-008-9243-1     Document Type: Article

References (47)

1. Friedman DS, O'Colmain BJ, Munoz B et al (2004) Eye diseases prevalence research group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564-572
2. Macular Photocoagulation Study Group (1982) Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 100:912-918
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: 2-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198-207
4. Lopez PF, Sippy BD, Lambert HM et al (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855-868
5. Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929-1934
6. Rakic JM, Lambert V, Devy L et al (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186-3193
7. Gragoudas ES, Adamis AP, Cunningham ET et al (2004) VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816
8. Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859-870
9. Rosenfeld PJ, Brown DM, Heier JS et al (2006) MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
10. Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390
11. Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1-9
12. Aggio FB, Farah ME, Silva WC, Melo GB (2007) Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 245:215-220
13. Rich RM, Rosenfeld PJ, Puliafito CA et al (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495-511
14. Yoganathan P, Deramo VA, Lai JC et al (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26:994-998
15. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372
16. Chen CY, Wong TY, Heriot WJ (2007) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study. Am J Ophthalmol 143:510-512
17. Emerson MV, Lauer AK, Flaxel CJ et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439-444
18. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68-73
19. Pedersen R, Soliman W, Lund-Andersen H, Larsen M (2007) Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 85:526-533
20. Jonas JB, Libondi T, Ihloff AK et al (2007) Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 85:563-565
21. Aisenbrey S, Ziemssen F, Völker M et al (2007) Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247:941-948
22. Abraham-Marin ML, Cortes-Luna CF et al (2007) Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: A pilot study. Graefes Arch Clin Exp Ophthalmol 245:651-655
23. Goff MJ, Johnson RN, McDonald HR et al (2007) Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27:432-438
24. Chen E, Kaiser RS, Vander JF (2007) Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 27:445-450
25. Aggio FB, Farah ME, Silva WC, Melo GB (2007) Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 245:215-220
26. Boyer DS, Antoszyk AN, Awh CC et al (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:246-252
27. Blinder KJ, Bradley S, Bressler NM et al (2003) Treatment of age-related macular degeneration with photodynamic therapy study group; verteporfin in photodynamic therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136:407-418
28. Aggio FB, Farah ME, de Melo GB et al (2007) Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 21:408-409
29. Fung AE, Rosenfeld PJ, Reichel E (2006) The International intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349
30. Spandau UH, Jonas JB (2006) Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 142:1068-1070
31. Shah CP, Hsu J, Garg SJ et al (2006) Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 142:1070-1072
32. Chan CK, Meyer CH, Gross JG et al (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27:541-551
33. Ronan SM, Yoganathan P, Chien FY et al (2007) Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 27:535-540
34. Gamulescu MA, Framme C, Sachs H (2007) RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 245:1037-1040
35. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257-261
36. Luthra S, Narayanan R, Marques LE et al (2006) Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512-518
37. Bakri SJ, Cameron JD, McCannel CA et al (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162-164
38. Costa RA, Jorge R, Calucci D et al (2006) Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47:4569-4578
39. Heiduschka P, Fietz H, Hofmeister S et al (2007) Tübingen bevacizumab study group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814-2823
40. Steinbrook R (2006) The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355:1409-1412
41. Raftery J, Clegg A, Jones J et al (2007) Ranibizumab (lucentis) versus bevacizumab (avastin): Modelling cost effectiveness. Br J Ophthalmol 91:1244-1246
42. Dhalla MS, Shah GK, Blinder KJ et al (2006) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26:988-993
43. Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114:1179-1185
44. Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245:1273-1280
45. Augustin AJ, Puls S, Offermann I (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration: Verteporfin PDT, bevacizumab, and dexamethasone. Retina 27:133-140
46. Ahmadieh H, Taei R, Soheilian M et al. (2007) Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 7:10
47. Spaide RF (2006) Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141:149-156